We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
- Authors
Yuko Muraki; Takeshi Fujita; Masaaki Matsuura; Isao Fuke; Sadao Manabe; Toyokazu Ishikawa; Yoshinobu Okuno; Kouichi Morita
- Abstract
Background: West Nile virus (WNV) belonging to the genus Flavivirus of the family Flaviviridae causes nervous system disorder in humans, horses and birds. Licensed WNV vaccines are available for use in horses but not for humans. We previously developed an inactivated West Nile virus vaccine (WN-VAX) using a seed virus from West Nile virus (WNV NY99) that was originally isolated in New York City in 1999. In this study, we report the immunogenicity of WN-VAX in both mice and non-human primates. Findings: The WN-VAX immunized mice showed protection against lethal infection with WNV NY99. The challenge test performed on mice passively immunized with serum from other mice that were previously immunized with WN-VAX confirmed that the neutralizing antibody titers of more than 1log10 protected the passively immunized mice from WNV lethal infection. Furthermore, monkeys (Macaca fascicularis) immunized three times with 2.5 µg, 5 µg or 10 µg/dose of WN-VAX exhibited neutralizing antibodies in their sera with titers of more than 2log10 after the second immunization. Conclusions: The WN-VAX was protective in mice both by active and passive immunizations and was immunogenic in monkeys. These results suggest that the vaccine developed in this study may be a potential WNV vaccine candidate for human use.
- Subjects
WEST Nile fever; WEST Nile virus; MOUSE diseases; MONKEY diseases; IMMUNIZATION; IMMUNOGLOBULINS; VACCINATION
- Publication
Virology Journal, 2015, Vol 12, Issue 1, p1
- ISSN
1743-422X
- Publication type
Article
- DOI
10.1186/s12985-015-0282-8